In a bid to improve efficiency and reduce costs UK in vitro
diagnostics company Axis-Shield is to shift the manufacture of
certain products from its site in Oslo, Norway to the company's
global headquarters in Dundee, Scotland.
BioProgress, a UK company specialising in the manufacture of
non-gelatin capsules, looks set to become only the second UK
biopharmaceutical company to brave the equity markets this year
with a transfer of its listing Nasdaq's...
Operating profit for Danish enzyme company Novozymes improved
marginally in the first quarter of 2003, despite the impact of
unfavourable exchange rates. On the back of favourable developments
in net financials, the company reports...
A new validation package for pharmaceutical applications has hit
the market. Provided by Markem corporation, the new package is
intended to assist companies, in performing validation of new
coding equipment and to ensure that a specific...
UK life sciences group Amersham has reported first-quarter 2003
sales of £381 million (€544m), flat on the same period of 2002 but
up 6 per cent if unfavourable currency impacts and discontinued
product sales were excluded. The results...
Architects of the new instruments for the Sixth Framework Programme
will be heartened by news that a German report on the country's
networks of competence has concluded that such arrangements
stimulate innovation and, in turn,...
US provider of virtual product development (VPD) technologies
MSC.Software has come up with a range of new software and services
packages targeted at the biomedical market and medical device
Research into genomes of the natural world took a step forward this
week with the announcement from Diversa corporation that it is to
jointly collaborate with the US Department of Energy's Joint Genome
Institute (JGI) to discover...
Danish Novo Nordisk plans to break ground on a €10 million
expansion of its insulin manufacturing facility in Clayton, US. The
company has awarded the contract to BE&K Engineering and Suitt
Construction for the 19,000-square-foot...
Outsourcing drug discovery functions is a rapidly growing trend
that has led to a nearly $2 billion (€1.7bn) industry worldwide,
according to a new study released this week by Kalorama
Information, and contract services in the field...
Balchem reported a small rise in net sales, up 3 per cent overall
during the first quarter of 2003, but said it was pleased with
results in light of the continued difficult economic environment.
Net earnings at the New York-based...
In a bid to increase European competitity in the global research
arena the European Commission announced new measures destined to
encourage public and private players across Europe to upgrade their
Paris, France-based speciality chemicals company Rhodia has
reported a disappointing set of first quarter figures that reflects
what the firm describes as "a difficult economic and geopolitical
environment" and "a trough...